ONA

ONA Regenerative Medicine is a biotechnology company specializing in the field of organ transplantation. The company also owns the world's first industrial platform for genome-edited miniature pig xenotransplantation. Holding exclusive patents on large-scale gene editing and cell quantitative partial reprogramming core technologies, its key expertise integrates gene editing + quantitative partial reprogramming + mRNA technology + Piggybac technology, enabling genomic editing exceeding 100kb-100Mb and breaking the international technical bottleneck for large-scale pig genome editing. Guided by the philosophy of "One Pig Fits All," ONA aims to create a large-scale genome-edited pig platform, providing an unlimited and industrial source of donors for nearly all clinical cells, tissues, and organ transplants, fundamentally solving the global donor organ shortage crisis. The company’s vision is to "create a world of donor freedom."